What we deliver
We turn metabolic-disease biology into decisions — mechanism-to-market strategy, biomarker and endpoint planning, competitive positioning, and scientific narrative, grounded in graded evidence, not hype.
A focused set of advisory services, each scoped to the specific scientific and strategic decision at hand. Engagements are partner-led, defined in writing, confidential, and built around a clear deliverable. Our engagements combine scientific interpretation, evidence strategy, and business-development perspective.
Strategic Scientific Memo
Hypothesis-driven analysis for board, investor, or internal decision-making. The central deliverable distills the question, the evidence, the options, and a clear, defensible recommendation — supported by the specialized services below when the scope calls for them.
01Mechanism-to-market strategy
For founders and platform teams turning strong biology into a path forward. Deliverable: a strategic memo linking mechanism to indication, evidence, and positioning.
02Metabolic landscape & Strategy Reports
For teams entering or repositioning in metabolic disease. Deliverable: an evidence-graded read of the field — a curated or published Strategy Report.
03Asset differentiation assessment
For BD, investors, and founders asking how an asset truly differs from the leaders and the pipeline. Deliverable: a differentiation and defensibility map.
04Biomarker & endpoint strategy
For clinical-development and translational teams. Deliverable: an endpoint and biomarker rationale that holds up under diligence and review.
05Clinical-trial evidence mapping
For investors and development teams. Deliverable: the trial and approval landscape, graded by evidence stage (approved / trial / emerging).
06White-space analysis
For founders and strategy teams seeking defensible ground. Deliverable: a scientific and strategic white-space and risk map.
07Scientific narrative development
For teams raising capital who need a story that survives scrutiny. Deliverable: refined narrative and technical positioning for decks and materials.
08Founder / CEO scientific positioning
For founder-CEOs representing their science to investors and partners. Deliverable: a positioning brief with messaging guardrails.
09Diligence support
For investors and BD wanting an independent read before committing. Deliverable: a diligence memo on mechanism, evidence, and risk — independent, and not a recommendation to transact.
10Advisory bench support
When a question needs adjacent expertise — neuroscience, cancer biology, behavioral health, legal/commercial, or translational program design — a focused advisory bench contributes within a scoped engagement.
Each engagement begins with a written scope defining the question, sources, assumptions, timeline, confidentiality, and output. Services can be combined into a single deliverable or sequenced across a longer relationship.
Scoped, confidential, deliverable-driven
Every engagement begins with a confidential scoping conversation and a short written scope before work starts — so the question, sources, assumptions, timeline, and output are agreed up front, and the relationship is organized around a clear, decision-ready deliverable rather than open-ended hours.
Scoping
Clarify the strategic question, decision context, and deliverable.
Written Scope
Define timeline, sources, assumptions, confidentiality, and output.
Discovery
Review decks, data, publications, patents, regulatory signals, and market context.
Research or Expert Input
Add targeted secondary research or KOL input when the question requires it.
Analysis & Synthesis
Translate evidence into strategic implications, risks, options, and recommendations.
Live Review
Discuss the deliverable, pressure-test assumptions, and clarify next steps.
Engagements are defined in writing before work begins. Client information and findings are treated as confidential. Integral BioStrategy provides scientific and strategic advisory only — legal, regulatory, investment, clinical, and medical advice are outside standard engagements unless separately scoped in writing with the appropriate qualified contributor.
Have a scientific strategy question?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]